Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin Takeuchi

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
International Journal of Hematology|June 23, 2011
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphomaKatsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, et al.
Leukemia Research|July 2, 2013
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOPYujin Kobayashi, Yoshihiro Hatta, Atsuko Hojo, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|December 16, 2014
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phaseKoiti Inokuchi, Takashi Kumagai, Eri Matsuki, et al.
Haematologica|May 30, 2013
Prognosis of patients with core binding factor acute myeloid leukemia after first relapseSaiko Kurosawa, Shuichi Miyawaki, Takuhiro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|December 4, 2013
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemiaTakashi Kumagai, Eri Matsuki, Koiti Inokuchi, et al.
Blood|November 26, 2010
A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|June 23, 2011
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphomaKatsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, et al.
Leukemia Research|July 2, 2013
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Experimental and Therapeutic Medicine|September 13, 2012
Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOPYujin Kobayashi, Yoshihiro Hatta, Atsuko Hojo, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|December 16, 2014
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phaseKoiti Inokuchi, Takashi Kumagai, Eri Matsuki, et al.
Haematologica|May 30, 2013
Prognosis of patients with core binding factor acute myeloid leukemia after first relapseSaiko Kurosawa, Shuichi Miyawaki, Takuhiro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|December 4, 2013
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemiaTakashi Kumagai, Eri Matsuki, Koiti Inokuchi, et al.
Blood|November 26, 2010
A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
Pageof 7